

North Yorkshire & York Area Prescribing Committee

Wednesday 5th April 2023
2pm – 4.30pm, virtual meeting via Microsoft Teams

Present

Name	Job Title	Organisation	Voting Member	Nov 2022	Dec 2022	Feb 2023	Mar 2023	Apr 2023
Ken Latta	Head of Medicines Optimisation	North Yorkshire Place	Y	Y	Y	Rachel Ainger	Y	Y
Dr Tim Rider	GP Prescribing Lead	North Yorkshire Place	Y	Y	Y	Y	Y	Y
Laura Angus	Head of Medicines Optimisation and Interim Chief Pharmacist at Humber, & North Yorkshire ICS	City of York Place	Y	Y	Y	Y	Y (from Item 15)	Fasial Majothi
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	City of York Place	Y	Y	Y	Y	Y	Apols
Dr William Ovenden	GP	City of York Place	Y	Y	Y	Y	Y	Y
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Y	Y	Y	Apols	Y
Dr Ben Walker (till Feb 2023)	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	Y	Y	Apols	Victoria Millson	Victoria Millson
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Y	Y	Jane Crewe
Dr Chris Hayes	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y (from 3pm)	Y	Apols	Y (from item 10)	Apols
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Y	Y	Apols	Y	Y
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Apols	Y (till item 9)	Apols	Y	Apols
Angela Hall	Public Health representative	North Yorkshire County Council	Y	Kurt Ramsden	Kurt Ramsden	Apols	Kurt Ramsden	Kurt Ramsden
Anita Dobson	Public Health representative	City of York Council	Y	Y (till 3.15pm)	Apols	Y	Apols	Resigned
Alison Levin	Finance representative	North Yorkshire Place	Y	Kathryn Shaw-Wright	Jo Horsfall	Jo Horsfall	Jo Horsfall	Apols
Hazel Mitford	Lay/patient representative		Y	Y (Till 3pm)	Y	Y	Apols	Apols
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	N	Y	Y	Y	Y	Y
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire Place	N	Y	Y	Y	Y	Y
Faisal Majothi	Medicines Optimisation Pharmacist	City of York Place	N	Y	Y	Y	Y	See above
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	N	Y	Y	Y	Y	See above
Sara Abbas-Llewelyn / Emily Parkes	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	N	X	X	X	X	Sara Abbas-Llewelyn
Ian Dean	LPC Representative		N	Apols	Y	Y	Y	Y
Dr Sally Tyrer	LMC Representative		N	X	X	X	X	X
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	N	Apols	X	For item 17	Y	Y

The meeting was quorate with 9 out of 14 currently appointed voting members (or their deputies) in attendance and present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees, and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Tim Rider.

Part 1

1. Apologies for absence and quoracy check

Shaun O'Connell, Laura Angus, Chris Hayes, Hazel Mitford, Stuart Parkes, Jo Horsfall, Richard Morris.

Note: City of York Public Health Team will no longer attend the APC following a review of their meeting commitments.

2. Declarations of interest

Declarations of interest:

The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available via the professional secretary.

Declarations of interest from today's meeting:

Nil declared.

3. Minutes of previous APC & decision summary of meeting held on 1st March 2023

The minutes of the March 2023 APC were approved as a true and accurate record.

4. Outcome of items referred to March 2023 IPMOC

Nil from March 2023 APC meeting.

Items previously referred to IPMOC still awaiting confirmation of scheme of delegation for decision-making by IPMOC.

5. Matters arising not on the agenda & declarations of AOB

Nil matters arising.

AOB – HRT prepayment certificate.

6. Action log

Valproate medicines for patients of child-bearing potential

LA still to circulate final approved version of SCG.

JC/SAL still to update the formulary websites.

Formulary Updates approved at March 2023 APC

JC/SAL are in process of updating Y&S and Harrogate formularies. ITEM NOW CLOSED.

Outstanding actions from previous APC meetings

North Yorkshire and York APC – Updated Terms of Reference and Scheme of Delegation

RDTC/LA to work further on tidying up language in NY&Y APC Terms of Reference and bring to future APC once IPMOC terms of reference plus scheme of delegation for ICB decision-making around medicines agreed. To come back to May 2023 APC.

Current vacancies in membership and non-attendance

To come back to May 2023 APC with paper on changes to operation of APC meetings.

Bicalutamide RAG status

Note: the practice on when to initiate the LHRH analogue in relation to the initiation of bicalutamide varies between urologists across NY&Y. APC discussed and agreed that both drugs should either be initiated in secondary care or that the GP initiates both drugs. Agreed further discussion required with urologists to arrive at a consensus across NY&Y to avoid any confusion/prescribing issues for GPs, and so that patient expectations are clear.

Diazoxide for chronic intractable hypoglycaemia

KW/SM/JC to develop shared care guideline to be presented to future APC for approval. To come back to May 2023 APC.

Medical Devices Commissioning and Formulary Position

RDTG to review previous MCC commissioning positions on individual medical devices in Q1 2023/24.

Vulval treatment advice proforma - HDFT

SP/JC to make one last attempt at consulting with YSFT and adoption before APC makes a decision on approval. If needed, APC will approve just for HDFT. To come back to May 2023 APC.

Oral minoxidil for androgenic alopecia

ICB policy alignment group have confirmed they will review this particular policy across the ICB when the NICE TA for baricitinib is published. Agreed no further action for item for APC until this policy is reviewed by the ICB.

Vitamin D guidance - reviewed and updated

FM/SM still to add in additional information from York guidance; however, websites have been updated with interim approved version.

Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring 16 December 2020 – updated RCOphth guidelines

Work on adopting national shared care template is ongoing in NY&Y.

Melatonin YSTHFT shared care

APC agreed to remove from action log as on NY&Y Medicines Management Team workplan to bring a paper to APC in future re all the issues around melatonin within NY&Y. Noted that service provision across NY&Y for melatonin/sleep clinics is variable. Look to adopt the TEWV SCG within NY&Y where there is service provision once it is approved.

Part 2 – Governance

7. Update on meeting of APC membership to help improve operation of the APC

A verbal update was given on the meeting of the APC membership held two weeks ago to help improve operation of the APC. The PowerPoint slides used at the meeting to support the discussions have been previously circulated to APC members.

A paper has been developed as an output of that process, with the aims to:

- Enhance engagement of the whole APC membership and attending partners
- Ask members to help shape APC processes for a smoother running APC
- Improve efficiency and address any frustrations associated with APC processes
- Create an all-round more satisfying, professional and comfortable APC meeting where all attendees feel (and are made to feel) comfortable to attend and speak

This paper will be presented at the May 2023 APC meeting.

A calendar of dates for deadlines for submission of agenda items is being created and will be circulated.

Part 3 – Mental Health

8. Nil this month.

Part 4 – Formulary Issues

9. **Appeals against previous APC decisions**

None received.

10. **Formulary NICE TAs and MHRA Drug Safety Update – February 2023**

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
- TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
- TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
- TA866: Regorafenib for previously treated metastatic colorectal cancer
- TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis
- TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
- TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
- HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene

All the above TAs are NHSE-commissioned and would therefore have no cost impact to the ICB.

The ICB-commissioned drugs in the following TAs to be reflected in the formulary as RED drugs for this indication in the relevant chapters with links to the TAs:

- TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis

The ICB-commissioned drugs in the following TAs to be reflected in the formulary as AMBER SI for paediatrics to mirror the Leeds formulary position:

- TA863: Somatrogen for treating growth disturbance in children and young people aged 3 years and over

The NHSE-commissioned drugs in the following TAs were received for information:

- TA867: Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)
- TA869: Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)

Note: all the above recommendations fall within the delegated authority of the APC.

Medicines Safety (MHRA Drug Safety Update – February 2023)

The group noted the drug safety updates for February 2023. The links are to be added to the relevant sections of the formulary.

ACTION:

- **JC/SAL to update the formulary websites.**

11. Other formulary issues

Nil this month.

12. New Drug Applications

Buprenorphine long-acting injection (Buvidal®)

The APC discussed the formulary application received for Buprenorphine long-acting injection (Buvidal®) from North Yorkshire Council Public Health.

Requested for treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

The APC agreed to approve as a RED drug within service commissioned by North Yorkshire Council as an alternative option for consideration to buprenorphine sublingual preparations and methadone oral solution in patients meeting one of the following criteria:

1. travel abroad
2. have work or study commitments
3. have mobility issues
4. live in rural areas where access to community pharmacies providing substance misuse services will be difficult
5. have regular release from custody on license for short periods
6. have highly complex lifestyles, where diversion is probable and/or safe home storage is unlikely

The model of supply proposed is via substance misuse clinics in North Yorkshire to hold as stock under a Home Office license. It will not be supplied on prescription for patients to collect from community pharmacy.

This decision is subject to confirmation of management of acute withdrawal in patients on Buvidal® admitted to secondary care, and confirmation of process for updating patient records in a timely manner to show they are on Buvidal®.

Note: the decision fell within the delegated authority of the APC and that all costs would be borne by the local authority as the commissioner of substance misuse services.

ACTION:

- **JC/SAL to update the formulary websites.**
- **KR to confirm of management of acute withdrawal in patients on Buvidal® admitted to secondary care, and confirm of process for updating patient records in a timely manner to show they are on Buvidal®.**

Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM)

The APC discussed the formulary application received for Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM). Requested as option in children & adults with Type 1 or Type 2 diabetes on multiple daily insulin injections and including pregnant women, as outlined in NICE guidance

- <https://www.nice.org.uk/guidance/ng28>
- <https://www.nice.org.uk/guidance/ng17>
- <https://www.nice.org.uk/guidance/ng18>
- <https://www.nice.org.uk/guidance/ng3>

The APC discussed the evidence and cost impact presented in the application. It felt an educational programme needed to be in place to support primary care prescribing and appropriate use of the product. Note: forms part of an updated HNY CGM policy and that need

to manage patient expectations/demand.

The application was approved as AMBER specialist recommendation for both type 1 and type 2 diabetes patients subject to ICB approval of the overall CGM policy and an educational programme being in place for primary care. The same formulary status will also apply to Freestyle Libre 2.

ACTION:

- **JC/SAL to update the formulary websites once recommendation approved by ICB as part of an update HNY policy for CGM.**

13. Compassionate use/free of charge scheme requests

Nil this month.

14. RMOC update

Nil this month.

Part 5 – Shared Care and Guidelines (non-mental health)

15. Shared care guidelines for approval

Nil this month.

16. Guidelines for recognition and management of non- IgE cow's milk allergy in children – partial update

Following on from the approval and publication of the Guidelines for recognition and management of non- IgE cow's milk allergy in children, there has been feedback from both GP practices and some of the manufacturers that has triggered a partial update of the guideline; the specific changes are listed within the change history table on page 18.

The APC discussed and agreed that some clarifications to p6 were required before it was in a position to be approved for this updated guideline: Step 2-2 Re-challenge with cow's milk using iMAP guidelines after a 4-week period (can be omitted when symptoms are severe).

ACTION:

- **CR to seek clarifications to p6 before guideline is returned to APC for approval: Step 2-2 Re-challenge with cow's milk using iMAP guidelines after a 4-week period (can be omitted when symptoms are severe).**

17. NY&Y Migraine pathway

Updated version approved to include latest 30-day NICE TA for eptinezumab for preventing migraine published on 1st March 2023.

Noted that the decision fell within the delegated authority of the APC.

ACTION:

- **JC/SAL to update the formulary websites.**

Part 6 – Other Items of Business

18. Nil this month.

Part 7 – Standing Items (for information only)

19. IPMOC minutes – February 2023

Circulated for information.

20. **TEWV D&T minutes – November 2022**
Not yet available.
21. **York & Scarborough Trust Drug and Therapeutics Committee minutes – since November 2022**
Not yet available.
22. **Harrogate Trust Medicines and Therapeutics Group minutes – since September 2022**
Not yet available.
23. **County Durham & Tees Valley APC minutes – January 2023**
Circulated for information.
24. **Yorkshire ICS APC minutes – since November 2022**
Not yet available.
25. **Humber APC minutes – March 2023**
Not yet available.
26. **Humber APC decisions & recommendations – March 2023**
Circulated for information.
27. **RDTIC Monthly Horizon scanning – March 2023**
Circulated for information.
28. **NENC Medicines Committee decision sSummary – February 2023**
Circulated for information.

Any Other Business

HRT prepayment certificate

A general discussion took place on the practicalities for prescription writing and dispensing with regard to the new national HRT prepayment certificates from April 2023. It was noted that feedback has already been flagged up nationally to DHSC via groups such as the PSNC.

Formulary applications received for May 2023 meeting

The APC have received the following formulary applications to date for the May 2023 APC meeting:

- Nil to date.

Date and time of next meeting

Wednesday 3rd May 2023, 2pm – 4.30pm, virtual meeting via Microsoft Teams